Avantor (NYSE:AVTR) and Pacific Biosciences of California (NASDAQ:PACB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Institutional & Insider Ownership
78.0% of Avantor shares are owned by institutional investors. Comparatively, 71.6% of Pacific Biosciences of California shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of recent ratings and price targets for Avantor and Pacific Biosciences of California, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacific Biosciences of California||0||3||1||0||2.25|
Avantor presently has a consensus price target of $20.57, indicating a potential upside of 13.52%. Pacific Biosciences of California has a consensus price target of $8.00, indicating a potential upside of 58.73%. Given Pacific Biosciences of California’s higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Avantor.
This table compares Avantor and Pacific Biosciences of California’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacific Biosciences of California||-139.22%||-136.85%||-68.30%|
Valuation and Earnings
This table compares Avantor and Pacific Biosciences of California’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pacific Biosciences of California||$78.63 million||9.80||-$102.56 million||($0.76)||-6.63|
Avantor has higher earnings, but lower revenue than Pacific Biosciences of California.
Avantor beats Pacific Biosciences of California on 6 of the 9 factors compared between the two stocks.
Avantor Company Profile
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.